Kudos to the @BRS_DCU for organising a fantastic research day. A great program of talks and posters capturing the diverse biological research happening in @DcuBiotech and other areas of @DCUFSH (1/3)
Dr Denis Collins @coileain, from the DCU National Institute for Cellular Biotechnology (NICB) @nicb_dcu, with colleagues, have developed a blood test that can identify which patients will respond to certain breast cancer therapies.
Read here: https://t.co/pP1n43lIqX
Exciting postdoc position currently available investigating antibody-drug conjugate based drug combinations in ovarian, endometrial, and gastric cancers @DCU@DCU_Cancer@Neil_Conlon
🚨 Exciting News! 🎉 We’re hiring!
👩🔬🧑🔬
We have a postdoc position available for an industry-collaborative project working on antibody-drug conjugate based drug combinations in ovarian, endometrial, and gastric cancers 🧫🧬
Full details:
https://t.co/kYUUuEX4UT
Do you lie awake at night and wonder what effect Tyrosine Kinase Inhibitors have on the internalisation rates of T-DM1 and T-DXd in HER2+ breast cancer cell lines? Well then I've got the poster for you @News_IACR
@nicb_dcu @DCUFSH@CCRTIreland@coileain@BRS_DCU
Delighted to have my poster on the potential influence the retinoic acid pathway has in the development of treatment resistance in HER2+ Breast Cancer shortlisted @News_IACR @nicb_dcu @DCU
It was fantastic to kick off the @GynocareAction meeting with an overview of some of the new targeted therapies for ovarian cancer that we are working on in @nicb_dcu @DcuBiotech. Thanks, @jeancallejaagiu and the local organisers for the invitation